Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285)

Henan Lingrui Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	3,514	3,307	2,998	2,690	2,328	2,154
Other Revenue	2.87	3.98	3.44	3.48	3.44	3.35
Revenue	3,517	3,311	3,002	2,694	2,332	2,157
Revenue Growth (YoY)	9.91%	10.31%	11.45%	15.52%	8.09%	5.06%
Cost of Revenue	925.65	888.53	837.53	707.97	547.68	493.33
Gross Profit	2,591	2,423	2,164	1,986	1,784	1,664
Selling, General & Admin	1,738	1,675	1,608	1,483	1,342	1,217
Research & Development	113.56	109.65	125.07	86.21	97.76	78.67
Other Operating Expenses	46.46	44.84	40.54	37.4	28.4	33.45
Operating Expenses	1,902	1,834	1,775	1,609	1,468	1,335
Operating Income	689.5	588.93	389.07	376.45	316.2	328.69
Interest Expense	-	-0.2	-1.14	-1.9	-1.1	-9.96
Interest & Investment Income	63.9	55.87	86.61	43.03	57.89	12.36
Currency Exchange Gain (Loss)	-0.01	-0.01	0	-0	0	-0
Other Non Operating Income (Expenses)	-0.01	-1.69	-1.75	-1.7	7.08	-0.29
EBT Excluding Unusual Items	753.38	642.9	472.79	415.88	380.07	330.8
Impairment of Goodwill	-	-	-	-	-0.5	-
Gain (Loss) on Sale of Investments	-2.23	0.12	5.93	0.05	-0.05	-9.99
Gain (Loss) on Sale of Assets	-0.93	-0.63	-0.1	-20.32	-2.95	-0.4
Asset Writedown	-1.83	-1.83	-	-	-27.8	-
Other Unusual Items	19.3	12.49	38.42	17.74	15.43	20.89
Pretax Income	767.69	653.04	517.03	413.35	364.2	341.28
Income Tax Expense	103.48	84.93	51.73	50.85	39.82	48.14
Earnings From Continuing Operations	664.2	568.12	465.3	362.5	324.38	293.15
Minority Interest in Earnings	-0.04	-0.01	-0	-0.96	1.11	1.29
Net Income	664.16	568.11	465.3	361.54	325.49	294.44
Net Income to Common	664.16	568.11	465.3	361.54	325.49	294.44
Net Income Growth	29.78%	22.09%	28.70%	11.08%	10.55%	21.04%
Shares Outstanding (Basic)	562	561	557	556	568	575
Shares Outstanding (Diluted)	566	566	568	567	568	575
Shares Change (YoY)	0.01%	-0.30%	0.26%	-0.24%	-1.22%	-2.60%
EPS (Basic)	1.18	1.01	0.84	0.65	0.57	0.51
EPS (Diluted)	1.17	1.00	0.82	0.64	0.57	0.51
EPS Growth	29.77%	22.47%	28.37%	11.34%	11.91%	24.27%
Free Cash Flow	681.65	792.23	807.92	768.78	378.71	391.12
Free Cash Flow Per Share	1.21	1.40	1.42	1.36	0.67	0.68
Dividend Per Share	0.800	0.800	0.600	0.500	0.400	0.300
Dividend Growth	33.33%	33.33%	20.00%	25.00%	33.33%	100.00%
Gross Margin	73.68%	73.17%	72.10%	73.72%	76.51%	77.13%
Operating Margin	19.61%	17.78%	12.96%	13.98%	13.56%	15.24%
Profit Margin	18.89%	17.16%	15.50%	13.42%	13.96%	13.65%
Free Cash Flow Margin	19.38%	23.92%	26.91%	28.54%	16.24%	18.13%
EBITDA	762.88	664.74	463.4	447.63	384.66	396.26
EBITDA Margin	21.69%	20.07%	15.44%	16.62%	16.50%	18.37%
D&A For EBITDA	73.38	75.81	74.33	71.18	68.46	67.57
EBIT	689.5	588.93	389.07	376.45	316.2	328.69
EBIT Margin	19.61%	17.78%	12.96%	13.98%	13.56%	15.24%
Effective Tax Rate	13.48%	13.00%	10.01%	12.30%	10.93%	14.11%
Revenue as Reported	3,517	3,311	3,002	2,694	2,332	2,157
Advertising Expenses	-	265.07	295.91	-	356.56	236.93

Source: S&P Capital IQ. Standard template. Financial Sources.